Alios BioPharma commences dosing in Phase I trial for RSV infection

31st May 2013 (Last Updated May 31st, 2013 05:34)

Clinical-stage biotechnology company Alios BioPharma has commenced patient dosing with nucleoside analog ALS-8176 in a Phase I trial to treat respiratory syncytial virus (RSV) infection.

RSV

Clinical-stage biotechnology company Alios BioPharma has commenced patient dosing with nucleoside analog ALS-8176 in a Phase I trial to treat respiratory syncytial virus (RSV) infection.

A structurally novel, anti-respiratory syncytial virus (RSV) nucleoside analog, ALS-8176 is the only known analog that is currently being developed for the treatment of acute RSV infection.

Preclinical studies demonstrated the potent anti-viral activity of the investigational compound across multiple strains of RSV by targeting the RSV polymerase.

Alios BioPharma chief executive officer Dr Lawrence Blatt said ALS-8176 has the potential to become an effective first-line antiviral therapy for RSV infection, for which only few treatments are currently available.

"The advancement of ALS-8176 for RSV, together with the recently reported positive clinical data with VX-135 (formerly ALS-2200, an anti-HCV nucleotide analog), demonstrates the broad capabilities of the Alios discovery platform," Blatt said.

"We are currently utilising this platform to screen against several infectious diseases with high unmet medical needs."

Designed to assess the safety, tolerability and pharmacokinetics of single ascending doses and multiple ascending doses of orally administered ALS-8176, the randomised, double-blind study will include around 90 healthy adult volunteers.


Image: Transmission electron micrograph of respiratory syncytial birus. Photo: Courtesy of MarcoTolo.